Reappraisal of TDP-43 pathology in FTLD-U subtypes

Ian R Mackenzie1, Manuela Neumann2

  • 1Department of Pathology, Vancouver General Hospital, University of British Columbia, 855 West 12th Avenue, Vancouver, BC, V5Z 1M9, Canada. ian.mackenzie@vch.ca.

Insights

This study refines classification of frontotemporal lobar degeneration with TDP-43 pathology. Findings suggest current criteria need adjustment for accurate subtyping of FTLD-TDP cases.

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Molecular Biology

Background:

  • Frontotemporal lobar degeneration with tau-negative, ubiquitin-immunoreactive pathology (FTLD-U) is subclassified by neuronal inclusion type and distribution.
  • Transactive response DNA-binding protein 43 kDa (TDP-43) is the primary ubiquitinated protein in most FTLD-U cases.
  • Current FTLD-U classification criteria, based on ubiquitin immunohistochemistry (IHC), may not perfectly translate to TDP-43 IHC due to subtle differences in detected pathological changes.

Purpose of the Study:

  • To formally re-evaluate TDP-43-immunoreactive pathological features in FTLD-U subtypes.
  • To refine the existing classification system for FTLD based on TDP-43 immunohistochemistry.
  • To assess the applicability of current FTLD-U subtype criteria using TDP-43 IHC.

Main Methods:

  • Retrospective analysis of 78 cases with frontotemporal lobar degeneration.
  • Immunohistochemistry (IHC) for ubiquitin and TDP-43 was performed.
  • Systematic evaluation of neuronal inclusions (neuronal cytoplasmic inclusions - NCI, dystrophic neurites - DN) and their distribution.

Main Results:

  • 81% of cases were classified into common FTLD-U subtypes (A, B, C) using TDP-43 IHC.
  • TDP-43 IHC revealed consistent intra-group features and clear inter-group differences for subtypes A and C, largely mirroring ubiquitin IHC findings.
  • Type B cases showed distinct TDP-43 IHC profiles with diffuse granular NCI and thread-like profiles, differing significantly from ubiquitin IHC. Fifteen cases, including 12 with C9orf72 mutations, exhibited features of multiple FTLD-TDP subtypes.

Conclusions:

  • Pathological criteria for subtyping FTLD-TDP may require refinement to account for variations in NCI and neurite morphology observed with TDP-43 IHC.
  • A significant subset of cases, particularly those with C9orf72 mutations, present with mixed FTLD-TDP pathological features, complicating classification.
  • Further research is needed to optimize diagnostic criteria for complex FTLD-TDP cases.

Related Concept Videos